StockData
DaVita Inc. logo

DaVita Inc. (DVA) KPIs and segments

DVANYSEServices-Misc Health & Allied Services, NECFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3042% below fair value
$173.00−1.22 (-0.70%)

Close on Nov 17, 2026Market cap $10.88BP/E 12.7Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của DaVita · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của DaVita: 57 chỉ số vận hành, trong đó có U.S. Dialysis Treatments, U.S. Average Treatments per Treatment Day và U.S. Average Treatments per Normalized Day, lấy từ 180 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
U S Dialysis And Related Lab Services with Intersegment($M)
3,0503,0122,9422,9802,9132,8232,9062,8412,756
U. S. Dialysis And Related Lab Services($M)
3,0283,0002,9212,9682,8972,8112,8902,828
U S Dialysis($M)
2,8112,8162,9062,8412,7322,721
Other Operating Segments with Intersegment($M)
552557498567455486415430376362342
Other Operating Segment($M)
550554494564452483412425374359339358
U. S. Dialysis And Related Lab Services($M)
544538506530523476549550
U S Dialysis($M)
476496549550526444
Other Operating Segment($M)
-18.657.15.8337.31.2256.7-2.8198.813.9-18.6-11.59.63
Other Operating Segment($M)
-33.2-28.7-13.6-23.5-33.3-17.8-29.7-31.9-19.2-18.5-16.1-21.7
U S Dialysis($M)
-114-139-120-106-105-137
U. S. Dialysis And Related Lab Services($M)
-126-141-88.4-133-103-114-120
U.S. Dialysis Treatments2
7,329,6447,226,6007,029,5257,264,5207,242,7257,186,2177,040,5197,278,6057,350,7847,265,4447,151,5127,254,559
U.S. Dialysis Treatment Days(ngày)
797877797978777979787878
U.S. Normalized Treatment Days(ngày)
797877807977
U.S. Average Treatments per Treatment Day1
92,78092,64991,65091,60891,68092,13191,79391,78693,04893,14792,15992,533
U.S. Treatments per Day YoY Growth(%)
1.2%0.6%-0.2%-0.2%-1.5%-1.1%-0.4%-0.8%0.6%0.5%-0.3%1.0%
U.S. Average Treatments per Normalized Day1
92,54692,64991,88991,37891,91391,554
U.S. Treatments per Normalized Day YoY Growth(%)
0.7%0.6%0.4%-0.7%-1.0%-0.8%
U.S. Normalized Non-Acquired Treatment Growth YoY(%)
0.4%0.3%0.1%-0.6%-0.6%-0.8%-0.6%-0.3%-0.2%0.4%0.4%0.7%
Total Global Outpatient Dialysis Patients
298,100298,500296,300295,000293,200283,100282,000281,100265,400265,100258,600250,200
Total Global Outpatient Dialysis Centers2
3,2693,2663,2623,2423,2473,1753,1733,1663,1133,1243,0923,042
U.S. Outpatient Dialysis Centers (Ending)6
2,6712,6712,6662,6572,6622,6622,6612,6572,6602,6722,6652,675
U.S. Centers Operated at Beginning of Period
2,6712,6662,6572,6622,6622,6612,6572,6602,6722,6652,6752,694
U.S. Centers Acquired
217000100-690
U.S. Centers Developed (De Novo)
32290-3610-45215
U.S. Centers Net Change in Non-Owned Managed Centers
-10000-21000-82
U.S. Centers Sold and Closed (Consolidated)
000000-3-10-17-80
U.S. Centers Closed (Non-Owned Managed)
-200-9-1-1-1-11-113-5-51
International Outpatient Dialysis Centers (Ending)7
5985955965852,6622,6625125092,6602,672427367
International Countries of Operation
141414141413131313131211
International Centers Operated at Beginning of Period
5955965852,6622,6625125092,6602,6724273672,694
International Centers Acquired
249600111860-55670
International Centers Developed (De Novo)
111-5300-7300-10
International Centers Net Change in Non-Owned Managed Centers
4020004-390-5-3-1
International Centers Sold and Closed (Consolidated)
-3-4-1-100-1-25-2001
International Centers Closed (Non-Owned Managed)
-100-2-30012-13-3-445
U.S. Dialysis Average Patient Service Revenue per Treatment($)
415416418423411405400396394390385386
U.S. Dialysis Patient Care Costs per Treatment($)
280277280280274268272265257255255263
U.S. Dialysis General and Administrative Expenses per Treatment($)
43.1445.7945.4946.2844.5143.4340.1543.4441.0138.7938.3939.06
U.S. Dialysis Depreciation and Amortization per Treatment($)
19.7020.2622.0722.5021.5721.8222.2821.6223.2122.0824.1724.94
U.S. Dialysis Total Operating Revenues($M)2
3,0503,0122,9423,0762,9802,9132,8232,8882,9062,8412,7562,809
U.S. Dialysis Patient Service Revenues($M)4
3,0443,0052,9353,0702,9742,9072,8172,8812,9002,8352,7502,802
Medicare and Medicare Advantage (U.S. Dialysis Patient Service Revenue)($M)
1,7561,7491,6751,7571,7151,6601,6091,6151,6421,5871,5321,562
Medicaid and Managed Medicaid (U.S. Dialysis Patient Service Revenue)($M)
228227213233215218207222217215210205
Other Government (U.S. Dialysis Patient Service Revenue)($M)
89.988.892.91038783.176.794.186.780.382.689.2
Commercial Payors (U.S. Dialysis Patient Service Revenue)($M)
970940954978957947925951955953926947
U.S. Dialysis Other Revenues($M)1
776666666666
Management and Administrative Service Fees (U.S. Dialysis)($M)
6.806.506.306.406.30666.106.205.906.106.40
U.S. Dialysis Total Operating Expenses($M)4
2,5062,4742,4362,5212,4502,3912,3472,3922,3572,2912,2302,365
U.S. Dialysis Patient Care Costs($M)
2,0542,0051,9692,0311,9811,9281,9131,9261,8931,8551,8251,909
U.S. Dialysis General and Administrative Expenses($M)
316331320336322312283316301282275283
U.S. Dialysis Depreciation and Amortization($M)
144146155163156157157157171160173181
U.S. Dialysis Equity Investment Income($M)
-8-8-8-10-10-7-6-8-8-6-6-8
U.S. Dialysis Segment Operating Income($M)
544538506556530523476496549550526444
U.S. Dialysis Patient Accounts Receivable($M)1
1,6841,7191,6951,6101,7041,8381,7221,6151,7071,8122,1801,632
U.S. Dialysis Days Sales Outstanding (DSO)(ngày)
515252495358555254597354
IKC Patients in Risk-Based Integrated Care Arrangements2
80,80064,90062,60066,00064,90064,40062,10070,40069,50071,30068,60058,000
IKC Annualized Medical Spend Under Risk-Based Arrangements($M)
6,4005,8005,4005,6005,5005,3005,2005,5015,4005,4005,3004,600
IKC Patients in Other Integrated Care Arrangements
3,1005,7006,3009,4009,4009,3009,30011,60013,90015,20014,20017,000
Total Ancillary Services and International Operating Revenues($M)4
5571,6061,0544151,9221,3559013421,5101,080704284
U.S. Integrated Kidney Care (IKC) Revenues($M)1
14416211619094152105165112114115160
Ancillary Other Revenues — Medicare & MA (IKC Shared Savings)($M)
13715210918385.91409915910497.4103143
U.S. Other Ancillary Services Revenues($M)1
109101098776777
Ancillary Other Revenues — Clinical Research & Transplant Software($M)
23.826.227.633.82921.115.614.713.515.515.214.6
International Dialysis Operations Revenues($M)2
398386372367352325302258258242219194
Ancillary Patient Service Revenues — Other Government (International)($M)
253236248242238225210199196177146124
Ancillary Patient Service Revenues — Commercial (International)($M)
13413611010898.691.287.856.858.662.470.267.7
Intersegment Revenue Eliminations($M)
-24-14-24-23-15-20-14-23-19-17-27-24
Total Ancillary Services and International Operating Loss($M)3
574463-3925554-1283-16-30-25
U.S. Integrated Kidney Care (IKC) Operating (Loss) Income($M)
440-1946-2126-2930-2-34-2127
U.S. Other Ancillary Services Operating Loss($M)
-6-8-6-4-4-5-4-7-2-2-6-19
International Dialysis Operations Operating Income($M)
-162530-4273630
Corporate Administrative Support Expenses($M)
-26-16-30-32-26-42-34-29-29-25-30-63
Routine Maintenance Capital Expenditures($M)
1121237410811990951191048685119
Development and Relocations Capital Expenditures($M)
474728384732485235393640
Acquisition Capital Expenditures($M)
3534-1108108535310518
Free Cash Flow (Non-GAAP)($M)3
276256140309604-45
Free Cash Flow — Trailing Twelve Months (LTM)($M)
9801,3081,2091,0249969471,4441,1621,1391,0386451,236
Operating Cash Flow — Trailing Twelve Months (LTM)($M)
1,8702,1932,0271,8871,8931,8622,3372,0221,9601,8101,4622,059
Distributions to Noncontrolling Interests($M)
-94-64-85-92-82-58-93-108-122-30-77-78
Consolidated Leverage Ratio (Net Debt to LTM Consolidated EBITDA)(×)4
3.383.373.343.263.373.343.273.033.173.103.293.15
Total Debt (Supplemental Schedule)($M)
10,83210,84810,69410,34510,31010,3309,7999,5119,6249,0489,1798,446
Net Debt (Non-GAAP)($M)
10,33710,17910,0509,6689,6049,6229,3618,7168,5538,6328,3848,066
Effective Interest Rate on Total Debt(%)
5.5%5.4%5.4%5.5%5.7%5.7%5.7%5.7%5.7%4.3%4.7%4.4%
Effective Interest Rate on Senior Secured Credit Facilities(%)
6.0%5.8%5.8%6.0%6.5%6.6%6.6%6.9%7.0%4.6%4.9%4.4%
Total Share Repurchase Amount($M)4
111348403331465446550367406376240286
Open Market Share Repurchase Amount($M)
74.7166203277233276518376240
Berkshire Hathaway Share Repurchase Agreement Amount($M)
36.5183200502321703200
Total Shares Repurchased (in Thousands)2
5942,2383,0052,6783,2743,0673,6602,3252,7342,6552,1192,904
Open Market Shares Repurchased (in Thousands)
4111,0181,3462,2761,6381,9213,4572,6552,119
Berkshire Hathaway Agreement Shares Repurchased (in Thousands)
1831,2201,6584021,6361,14620300
Average Price Paid per Repurchased Share($)2
18615513412314114414915614714011397.82
Open Market Repurchase Average Price Paid per Share($)
180161150141142149140113
Berkshire Hathaway Agreement Average Price Paid per Share($)
200150121141147156
Redeemable Noncontrolling Interests (Put Provisions)($M)
1,4841,5611,5251,5321,6451,6611,6671,6961,6331,5751,5041,499
Operating Lease Right-of-Use (ROU) Assets($M)2
2,4342,4302,3972,3972,3232,3392,3612,3942,4182,4582,4872,501
Operating Lease Liabilities — Current($M)
438440432426432429421410405405401394
Operating Lease Liabilities — Non-Current($M)
2,1852,1862,1622,1762,1002,1252,1612,2102,2372,2812,3122,330
Consolidated Operating Margin(%)3
14.0%16.3%14.1%15.5%14.8%15.9%13.6%17.2%16.4%15.9%15.8%12.4%
Consolidated Adjusted Operating Margin (Non-GAAP)(%)
15.7%16.3%14.1%16.2%15.1%16.3%13.6%14.9%16.4%15.9%14.6%
Consolidated G&A as % of Consolidated Revenues(%)
11.4%11.9%12.4%13.0%12.1%12.2%11.6%12.6%12.1%11.5%11.8%12.8%
Consolidated Effective Income Tax Rate(%)2
24.9%21.1%19.4%20.0%22.2%25.4%18.9%15.6%20.8%19.3%17.7%20.2%
Effective Income Tax Rate Attributable to DaVita Inc.(%)
28.7%25.6%25.1%27.7%31.3%31.9%24.9%19.9%26.5%24.2%21.5%29.0%
Adjusted Effective Income Tax Rate Attributable to DaVita Inc. (Non-GAAP)(%)
26.6%25.6%25.1%24.9%27.9%25.5%24.9%24.5%26.5%24.3%24.3%26.7%
U.S. Personal Consumption Expenditures: Health Care Services (BEA, SAAR)
3,858.703,790.303,699.903,667.003,614.903,529.803,464.703,417.803,358.203,288.203,244.403,159.40
Baxter International Inc. (NYSE: BAX) — Revenue($M)1
2,9762,9602,7012,9742,8352,8102,6252,7532,6992,6942,4902,729
Baxter International Inc. (NYSE: BAX) — Operating Income($M)
22521766-72917219158-435155179115304
Universal Health Services, Inc. (NYSE: UHS) — Revenue($M)1
4,7334,6384,4954,4864,4954,2844,1004,1143,9633,9083,8443,704
Universal Health Services, Inc. (NYSE: UHS) — Operating Income($M)
454517503517522500455472384436389331
Encompass Health Corp. (NYSE: EHC) — Revenue($M)
1,6101,5971,5871,5451,4781,4581,4551,4051,3511,3011,3161,247
Quest Diagnostics Inc. (NYSE: DGX) — Revenue($M)1
3,0973,0432,8952,8062,8162,7612,6522,6212,4882,3972,3662,288
Quest Diagnostics Inc. (NYSE: DGX) — Operating Income($M)
479459399386386438346361330355300267
Labcorp Holdings Inc. (NYSE: LH) — Revenue($M)1
3,8103,7313,5383,5163,5643,5273,3453,3293,2823,2213,1773,033
Labcorp Holdings Inc. (NYSE: LH) — Operating Income($M)
402452381268397394326216254295321-123
HCA Healthcare, Inc. (NYSE: HCA) — Revenue($M)
19,84920,23019,10919,51319,16118,60518,32118,28517,48717,49217,33917,303
Consolidated Operating Revenues($M)5
3,5783,5543,4163,6203,4203,3803,2243,2953,2643,1873,0713,146
Consolidated Operating Expenses and Charges($M)
3,0792,9752,9343,0592,9152,8422,7852,7292,7292,6802,5872,756
Consolidated General and Administrative Expenses($M)
409424422472414413374415394368363402
Consolidated Depreciation and Amortization($M)
165168178180178175177167187176187186
Goodwill and Asset Impairment Charges($M)
62.2000000000026.1
Equity Investment Income, Net($M)
8.208.208.309.9010.27.405.6010.33.705.506.705.40
Consolidated Operating Income($M)6
499579482561506538439565535506484390
Income Before Income Taxes($M)
359435341383309369286414373371372289
Income Tax Expense($M)
89.391.866.276.768.693.754.164.577.771.765.858.5
Consolidated Net Income($M)
269343275331240275232349296300306231
Less: Net Income Attributable to Noncontrolling Interests($M)
46.577.877.596.889.975.969.389.981.177.166.379.9
Diluted Earnings per Share($)
3.404.022.872.042.5822.502.502.65
Weighted-Average Diluted Shares(M)
65.566.168.973.877.481.385.88990.5
Operating Cash Flow($M)5
519490321541842324180548810799-135485
Capital Expenditures (Cash Flow Statement)($M)
160170102145166121143171139125121159
Stock-Based Compensation Expense($M)
29.22628.238.43932.829.827.426.624.324.530.1
Common Stock Repurchases (Cash Flow Statement)($M)
73182196275240284510365408362251272
Net Cash Used in Investing Activities($M)
-420-194-139-163-263-67.2-162-248-147-162-215-168
Net Cash Used in Financing Activities($M)
-271-270-213-415-5824.40-383-565-7.90-563319-403
Consolidated Total Assets($M)5
17,81717,71017,49917,48017,55617,49317,11917,28517,50417,02617,43116,894
Cash and Cash Equivalents($M)
4966696446767957975258801,159503431465
Patient Accounts Receivable, Net($M)
2,5092,4672,4592,4152,3332,4412,3222,1472,2672,3032,5951,987
Inventories($M)
162152142161139146151135129127146143
Goodwill($M)
7,5487,5917,5827,5457,5447,4667,4167,3757,2287,2017,2307,113
Intangible Assets, Net($M)
221229229222220212205197198192201203
Consolidated Total Liabilities($M)2
16,69116,63016,45116,32216,21515,94015,45915,19415,28414,60114,79514,150
Accounts Payable($M)
662716691696656594596547488494490515
Long-Term Debt($M)
10,65710,66410,51410,16410,18410,0799,5609,1769,2608,4529,0018,268

32 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • DaVita Inc.'s fiscal year ends December 31. In the project database and SEC filings, quarterly periods are labeled through Q3 2026 (ended September 30, 2026) and annual periods through FY2025 (ended December 31, 2025).
  • Quarterly flow metrics from Form 10-Q / 10-K cumulative tables (Outpatient Dialysis Center Rollforward, Note 2 Disaggregated Revenue by Payor Source, Note 18 Open Market vs. Berkshire Hathaway Share Repurchases, and Consolidated Cash Flows) have Q2, Q3, and Q4 split from year-to-date totals (Q2 = 6M − Q1, Q3 = 9M − 6M, Q4 = FY − 9M) on the same accounting basis.
  • For DaVita (UK) Limited (#05882395), operating subsidiary net profit is derived as Consolidated Group profit/loss minus Standalone Parent Company profit/loss from the audited UK Companies House statutory accounts (subject to intercompany management recharges and dividend eliminations).
  • Internal cross-checks verified at build time: (1) U.S. Dialysis + Ancillary/International sub-segment revenues less intersegment eliminations reconcile to Consolidated Operating Revenues ($13,643M in FY2025; $3,578M in Q3 2026); (2) U.S. + International ending outpatient dialysis centers reconcile exactly to Total Global Outpatient Dialysis Centers (2,657 + 563 = 3,220 at FY2025; 2,650 + 577 = 3,227 at Q3 2026); (3) all 46 U.S. states and D.C. in the 10-K map sum to Consolidated U.S. Outpatient Dialysis Centers.

Không hiện vì thiếu các kỳ gần đây (13)

  • Panama Outpatient Dialysis Centers (FY2025: 16 centers) — Entered Panama in FY2025; only 1 annual period available (requires 2 consecutive years).
  • Taiwan Outpatient Dialysis Centers (FY2016–FY2019: 15, 16, 2, 1 centers) — Discontinued after FY2019 following exit from Taiwan market; lacks recent periods.
  • India Outpatient Dialysis Centers (FY2016–FY2017: 21, 24 centers) — Discontinued after FY2017 following exit from India market; lacks recent periods.
  • Consolidated Variable Interest Entities (VIE) Assets and Liabilities (FY2016–FY2019) — XBRL tag discontinued after FY2019.
  • Goodwill by Segment (U.S. Dialysis vs. Ancillary Services, FY2016–FY2020) — Discontinued in Item 7 table after FY2020.
  • Fixed-Rate Debt Percentage and Capped Debt Percentage (FY2019Q1–FY2025Q3) — Not reported in Q4 2025 or FY2026 8-K supplemental debt schedules.
  • Noncontrolling Interest Contributions to Free Cash Flow (FY2022Q1–FY2026Q1) — Not reported as a separate reconciliation line in Q2–Q3 2026.
  • DaVita International Limited (#11015209) Middle East Turnover (FY2020–FY2023) — Reported as £0 / not separately broken out in FY2024–FY2025 statutory accounts.
  • DaVita (UK) Trading Limited (#07700242) Turnover Breakdown into Facilities Management Services vs. Management Recharges (FY2020–FY2023) — Not disaggregated in FY2024–FY2025 statutory accounts.
  • U.S. Census Bureau QSS Outpatient Care Centers Quarterly Revenue (REV6214TAXABL144QNSA) — Published with a 1-quarter lag (through Q2 2026 vs. DaVita Q3 2026).
  • Referring Nephrologists Count ('Nearly 5,200 nephrologists' in FY2025 10-K) — Excluded because disclosed only as a bound ('nearly').
  • Home Dialysis Patient Share ('More than 15% of our patients' in Community Care Report) — Excluded because disclosed only as a bound ('more than').
  • Kidney Transplant Recipients ('7,800+ DaVita patients' in Community Care Report) — Excluded because disclosed only as a lower bound ('+').

Dữ liệu cập nhật 2026-11-10.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Global Outpatient Dialysis Center Network, Patient Census & Rollforward

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của DaVita

See a number that looks wrong?